Transgene Signs Pre-Clinical AIDS Vaccine Manufacturing Agreement With ANRS and INSERM
2003年11月3日 - 2:01PM
PRニュース・ワイアー (英語)
Transgene Signs Pre-Clinical AIDS Vaccine Manufacturing Agreement
With ANRS and INSERM STRASBOURG, France, Nov. 3
/PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY; Nouveau Marche:
FR0005175080) announced today that it has entered into an agreement
with the French AIDS Research Agency (Agence Nationale de
Recherches sur le SIDA /ANRS) and the French Institute for Health
and Medical Research (Institut National de la Sante et de la
Recherche Medicale / INSERM) to construct and manufacture
pre-clinical lots of a novel AIDS vaccine. Transgene will make the
constructs consisting of Modified Vaccinia Ankara (MVA) vectors
carrying AIDS virus epitopes from Gag, Nef and Pol genes and will
manufacture the pre-clinical lots. INSERM, which owns the
intellectual property of the Nef protein fragments, will conduct
the immunological pre- clinical testing of the vaccine constructs
together with ANRS. Under the terms of this short-term service
agreement, Transgene will receive payment from ANRS. "We are
pleased to collaborate with the ANRS and INSERM on this serious
worldwide public health problem. We believe that this agreement is
further evidence of the broad capability of Transgene's technology
both in the construction and the manufacturing of recombinant
vaccines and vectors," said Jean-Francois Carmier, Chief Executive
Officer of Transgene. About Transgene: Transgene, based in
Strasbourg, France, is a biopharmaceutical company dedicated to the
discovery and development of therapeutic vaccines, immunotherapy
products, and delivery technologies for the treatment of diseases
for which there is no cure or adequate treatment at present, with a
focus on the treatment of cancer. Transgene has five products in
clinical development, two of which are in Phase II clinical trials
and three of which have completed Phase I clinical trials.
Transgene's proprietary vector technology platform consists of
adenovirus, poxvirus and non-viral vectors. This press release
contains forward-looking statements. Statements that are not
historical facts are based on Transgene's current expectations,
beliefs, estimates, forecasts and assumptions. Those statements are
not guarantees of future performance and involve certain risks,
uncertainties and assumptions which are difficult to predict.
Accordingly, actual outcomes and results may differ materially from
what is expressed in those forward-looking statements. Important
factors that may affect Transgene's future operating results
include the following: Transgene's collaboration agreement with
ANRS and INSERM may not provide Transgene with the anticipated
benefits when expected, if at all; Transgene's product candidates
may not demonstrate therapeutic efficacy; Transgene may be unable
to obtain regulatory approval for its product candidates;
Transgene's patent rights may not provide it with any benefit and
the patents of others may prevent it from commercializing its
products; Transgene may be unable to conduct its clinical trials as
quickly as it has predicted; Transgene may not have sufficient
resources to complete the research and commercialization of any of
its product candidates; competitors may develop technologies or
products superior to Transgene's technologies or products; and
other important factors described in Transgene's Annual Report on
Form 20-F for the year ended December 31, 2002 filed with the U.S.
Securities and Exchange Commission, including those factors
described in the section entitled "Risk Factors." DATASOURCE:
Transgene CONTACT: Michel Hubert, V.P., Business Development,
Transgene, +33-3-88-27-91-12; Julie Huang, +1-212-798-9814, or
Julio Cantre, +1-212-798-9779, both of Cohn & Wolfe for
Transgene; Marie-Carole de Groc, +33-1-58-47-95-07, or Odile
Rebattet, +33-1-58-47-95-06, both of Euro RSCG C&O
Copyright